Patents by Inventor Bruce H. Littman

Bruce H. Littman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210180069
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 17, 2021
    Applicant: PPL (BVI) Limited
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 10947539
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 16, 2021
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 10301629
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 28, 2019
    Assignee: PORTAGE PHARMACEUTICALS LTD.
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Publication number: 20190153450
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Application
    Filed: February 6, 2019
    Publication date: May 23, 2019
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Publication number: 20160136293
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Application
    Filed: June 11, 2014
    Publication date: May 19, 2016
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 6777424
    Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 17, 2004
    Assignee: Pfizer Inc.
    Inventor: Bruce H. Littman
  • Publication number: 20040157862
    Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.
    Type: Application
    Filed: January 22, 2004
    Publication date: August 12, 2004
    Applicant: Pfizer Inc
    Inventor: Bruce H. Littman
  • Publication number: 20020049198
    Abstract: The present invention provides methods and kits for treating osteoarthritis using an estrogen agonist/antagonist.
    Type: Application
    Filed: September 19, 2001
    Publication date: April 25, 2002
    Inventor: Bruce H. Littman
  • Patent number: 5298522
    Abstract: A method of producing analgesia and treating antiinflammatory disease in a human subject while avoiding proteinuria by administering 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide or a pharmaceutically-acceptable base salt thereof.
    Type: Grant
    Filed: January 22, 1993
    Date of Patent: March 29, 1994
    Assignee: Pfizer Inc.
    Inventors: Kelvin Cooper, Bruce H. Littman, Christopher J. Pazoles, Keith D. Wilner